drugset
drugset / Trial / NCT07024589

First-in-Human Trial of Oral AN2-502998

NCT07024589 ↗

Phase 1 Completed 72 enrolled AN2 Therapeutics, Inc
RandomizedSequentialDouble-blindBasic science

Summary

First-in-Human Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998

Timeline

Start
2025-08-04
Primary completion
2026-03-14
Completion
2026-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject AN2-502998 Unknown — Oral

Indications

No indication recorded.